Literature DB >> 7570466

Oxidants/antioxidants in idiopathic pulmonary fibrosis.

W MacNee1, I Rahman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7570466      PMCID： PMC1129017          DOI： 10.1136/thx.50.suppl_1.s53

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  48 in total

1.  Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis.

Authors:  A M Cantin; R C Hubbard; R G Crystal
Journal:  Am Rev Respir Dis       Date:  1989-02

2.  The prognosis of cryptogenic fibrosing alveolitis.

Authors:  B H Stack; Y F Choo-Kang; B E Heard
Journal:  Thorax       Date:  1972-09       Impact factor: 9.139

3.  Natural history and treated course of usual and desquamative interstitial pneumonia.

Authors:  C B Carrington; E A Gaensler; R E Coutu; M X FitzGerald; R G Gupta
Journal:  N Engl J Med       Date:  1978-04-13       Impact factor: 91.245

4.  Normal alveolar epithelial lining fluid contains high levels of glutathione.

Authors:  A M Cantin; S L North; R C Hubbard; R G Crystal
Journal:  J Appl Physiol (1985)       Date:  1987-07

5.  The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid.

Authors:  O I Aruoma; B Halliwell; B M Hoey; J Butler
Journal:  Free Radic Biol Med       Date:  1989       Impact factor: 7.376

6.  Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis.

Authors:  M A Johnson; S Kwan; N J Snell; A J Nunn; J H Darbyshire; M Turner-Warwick
Journal:  Thorax       Date:  1989-04       Impact factor: 9.139

7.  Oxygen radical production by alveolar inflammatory cells in idiopathic pulmonary fibrosis.

Authors:  J Strausz; J Müller-Quernheim; H Steppling; R Ferlinz
Journal:  Am Rev Respir Dis       Date:  1990-01

8.  [The effect of oral N-acetylcysteine on glutathione concentration in bronchoalveolar lavage of patients with fibrosing lung diseases].

Authors:  A Meyer; H Magnussen
Journal:  Med Klin (Munich)       Date:  1991-06-15

9.  Circulating immune complexes in the idiopathic interstitial pneumonias.

Authors:  R B Dreisin; M I Schwarz; A N Theofilopoulos; R E Stanford
Journal:  N Engl J Med       Date:  1978-02-16       Impact factor: 91.245

Review 10.  Oxidants, antioxidants, and respiratory tract lining fluids.

Authors:  C E Cross; A van der Vliet; C A O'Neill; S Louie; B Halliwell
Journal:  Environ Health Perspect       Date:  1994-12       Impact factor: 9.031
View more
  16 in total

Review 1.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  The oxidant-antioxidant balance in systemic sclerosis cases with interstitial lung involvement.

Authors:  Benan Musellim; Hande Ikitimur; Hafize Uzun; Gul Ongen
Journal:  Rheumatol Int       Date:  2006-09-02       Impact factor: 2.631

Review 3.  Role of transcription factors in inflammatory lung diseases.

Authors:  I Rahman; W MacNee
Journal:  Thorax       Date:  1998-07       Impact factor: 9.139

4.  In vivo antioxidant treatment protects against bleomycin-induced lung damage in rats.

Authors:  A Serrano-Mollar; D Closa; N Prats; S Blesa; M Martinez-Losa; J Cortijo; J M Estrela; E J Morcillo; O Bulbena
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

5.  Long-term administration of a small molecular weight catalytic metalloporphyrin antioxidant, AEOL 10150, protects lungs from radiation-induced injury.

Authors:  Zahid N Rabbani; Ines Batinic-Haberle; Mitchell S Anscher; Jie Huang; Brian J Day; Elaine Alexander; Mark W Dewhirst; Zeljko Vujaskovic
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-02-01       Impact factor: 7.038

Review 6.  Extracellular superoxide dismutase in pulmonary fibrosis.

Authors:  Fei Gao; Vuokko L Kinnula; Marjukka Myllärniemi; Tim D Oury
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

7.  Lipidomics revealed idiopathic pulmonary fibrosis-induced hepatic lipid disorders corrected with treatment of baicalin in a murine model.

Authors:  Changfeng Hu; Yiqi Wang; Yongsheng Fan; Haichang Li; Chunyan Wang; Jida Zhang; Shuijuan Zhang; Xianlin Han; Chengping Wen
Journal:  AAPS J       Date:  2015-03-12       Impact factor: 4.009

8.  Oxidative Modifications of Protein Tyrosyl Residues Are Increased in Plasma of Human Subjects with Interstitial Lung Disease.

Authors:  Subramaniam Pennathur; Anuradha Vivekanandan-Giri; Morgan L Locy; Tejaswini Kulkarni; Degui Zhi; Lixia Zeng; Jaeman Byun; Joao A de Andrade; Victor J Thannickal
Journal:  Am J Respir Crit Care Med       Date:  2016-04-15       Impact factor: 21.405

Review 9.  Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis.

Authors:  Rui-Ming Liu
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

10.  Preventive effect of chrysin on bleomycin-induced lung fibrosis in rats.

Authors:  Talat Kilic; Osman Ciftci; Asli Cetin; Hasan Kahraman
Journal:  Inflammation       Date:  2014-12       Impact factor: 4.092
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.